학술논문
First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
Document Type
Article
Author
Source
In Annals of Oncology August 2008 19(8):1470-1476
Subject
Language
ISSN
0923-7534